-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editors Insulin sensitivity in the human brain plays a key role in metabolic control, reducing food intake, improving whole-body insulin sensitivity, and regulating body fat mass and its distribution
.
Obesity and type 2 diabetes are often associated with brain insulin resistance, resulting in impaired brain regulation of peripheral metabolism
.
However, until now, no effective drug treatment has been found for insulin resistance in the brain
.
Recently, a research team from Germany recently published important research results in "Diabetes Care" (Diabetes Care), which showed that the SGLT2 inhibitor empagliflozin has the potential to treat insulin resistance in the brain, while reducing body fat and improving.
The whole body metabolism has a positive effect
.
Screenshot source: Diabetes Care This randomized, double-blind, placebo-controlled clinical trial included 40 patients with prediabetes (age 60±9 years; BMI 31.
5±3.
8 kg/m2)
.
Patients were randomly assigned to receive either empagliflozin (25 mg) or placebo daily
.
The researchers used functional magnetic resonance imaging (fMRI) to assess insulin sensitivity in the brain before and 8 weeks after treatment
.
To do this, patients are given insulin via a nasal spray
.
When hormones are absorbed through the nose, they can reach the brain directly
.
In addition, whole-body magnetic resonance imaging (MRI) was used to determine fat distribution
.
SGLT2 inhibitors increase insulin sensitivity in the brain The study found a significant interaction between time and treatment in the hypothalamic response to insulin
.
Post hoc analysis showed that only patients treated with empagliflozin had increased hypothalamic insulin responsiveness
.
Meanwhile, hypothalamic insulin action clearly mediated empagliflozin-induced reductions in fasting blood glucose and liver fat
.
While SGLT2 inhibitors did not reduce body weight, they did reduce body fat content
.
"Placebo treatment had no effect on insulin in the brain, whereas empagliflozin treatment significantly improved insulin's effect on brain activity," said the study's lead author, Professor Stephanie Kullmann
.
Credit: 123RF First to reverse brain insulin Potential Pharmacological Approach to Resistance The results demonstrate insulin resistance in the hypothalamus of prediabetic patients
.
Eight weeks of treatment with empagliflozin restored hypothalamic insulin sensitivity, a favorable response that may contribute to the beneficial effects of SGLT2 inhibitors
.
According to the paper, the findings suggest that "SGLT2 inhibitors are the first class of drugs found to have the potential to reverse insulin resistance in the brain, with potential benefits for lowering body fat and improving body metabolism
.
" We know that cardio-renal benefits are also A big advantage of SGLT2 inhibitors
.
So, is the improvement in brain insulin resistance also associated with the beneficial effects of SGLT2 inhibitors on the heart and kidneys? In the future, researchers will carry out further exploration and research on this
.
The relevant reading rate is less than 20%! AHA's latest call: diabetic patients, need to pay attention to these 7 types of "heart protection" strategies! "The Lancet" sub-issue in depth: Diabetes "sugar control concept" to change! 3 major indicators, 2 new technologies, 4 types of new treatments are worth paying attention to two "Lancet" articles: once a week, better than insulin! Dual Mechanisms for Type 2 Diabetes New Drug Metabolic Benefits Widespread "The Lancet" Sub-Journal Depth: These Innovative Therapies Possibly Change the Future of Type 2 Diabetes Treatment "The Lancet" Sub-Journal: Dapagliflozin Reduces New Diabetes by 33%, Two Pivotal Study Adds Evidence of Benefit! Source: 123RF Reference [1] Stephanie Kullmann et al, Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial, Diabetes Care (2021).
DOI: 10.
2337 /dc21-1136[2] Diabetes drug from the group of SGLT2 inhibitors normalizes insulin action in the brain.
Retrieved DECEMBER 20, 2021, from https://medicalxpress.
com/news/2021-12-diabetes-drug-group-sglt2- inhibitors.
htmlDisclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.
This article is also not a treatment plan recommendation
.
For guidance on treatment options, please visit a regular hospital
.
.
Obesity and type 2 diabetes are often associated with brain insulin resistance, resulting in impaired brain regulation of peripheral metabolism
.
However, until now, no effective drug treatment has been found for insulin resistance in the brain
.
Recently, a research team from Germany recently published important research results in "Diabetes Care" (Diabetes Care), which showed that the SGLT2 inhibitor empagliflozin has the potential to treat insulin resistance in the brain, while reducing body fat and improving.
The whole body metabolism has a positive effect
.
Screenshot source: Diabetes Care This randomized, double-blind, placebo-controlled clinical trial included 40 patients with prediabetes (age 60±9 years; BMI 31.
5±3.
8 kg/m2)
.
Patients were randomly assigned to receive either empagliflozin (25 mg) or placebo daily
.
The researchers used functional magnetic resonance imaging (fMRI) to assess insulin sensitivity in the brain before and 8 weeks after treatment
.
To do this, patients are given insulin via a nasal spray
.
When hormones are absorbed through the nose, they can reach the brain directly
.
In addition, whole-body magnetic resonance imaging (MRI) was used to determine fat distribution
.
SGLT2 inhibitors increase insulin sensitivity in the brain The study found a significant interaction between time and treatment in the hypothalamic response to insulin
.
Post hoc analysis showed that only patients treated with empagliflozin had increased hypothalamic insulin responsiveness
.
Meanwhile, hypothalamic insulin action clearly mediated empagliflozin-induced reductions in fasting blood glucose and liver fat
.
While SGLT2 inhibitors did not reduce body weight, they did reduce body fat content
.
"Placebo treatment had no effect on insulin in the brain, whereas empagliflozin treatment significantly improved insulin's effect on brain activity," said the study's lead author, Professor Stephanie Kullmann
.
Credit: 123RF First to reverse brain insulin Potential Pharmacological Approach to Resistance The results demonstrate insulin resistance in the hypothalamus of prediabetic patients
.
Eight weeks of treatment with empagliflozin restored hypothalamic insulin sensitivity, a favorable response that may contribute to the beneficial effects of SGLT2 inhibitors
.
According to the paper, the findings suggest that "SGLT2 inhibitors are the first class of drugs found to have the potential to reverse insulin resistance in the brain, with potential benefits for lowering body fat and improving body metabolism
.
" We know that cardio-renal benefits are also A big advantage of SGLT2 inhibitors
.
So, is the improvement in brain insulin resistance also associated with the beneficial effects of SGLT2 inhibitors on the heart and kidneys? In the future, researchers will carry out further exploration and research on this
.
The relevant reading rate is less than 20%! AHA's latest call: diabetic patients, need to pay attention to these 7 types of "heart protection" strategies! "The Lancet" sub-issue in depth: Diabetes "sugar control concept" to change! 3 major indicators, 2 new technologies, 4 types of new treatments are worth paying attention to two "Lancet" articles: once a week, better than insulin! Dual Mechanisms for Type 2 Diabetes New Drug Metabolic Benefits Widespread "The Lancet" Sub-Journal Depth: These Innovative Therapies Possibly Change the Future of Type 2 Diabetes Treatment "The Lancet" Sub-Journal: Dapagliflozin Reduces New Diabetes by 33%, Two Pivotal Study Adds Evidence of Benefit! Source: 123RF Reference [1] Stephanie Kullmann et al, Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial, Diabetes Care (2021).
DOI: 10.
2337 /dc21-1136[2] Diabetes drug from the group of SGLT2 inhibitors normalizes insulin action in the brain.
Retrieved DECEMBER 20, 2021, from https://medicalxpress.
com/news/2021-12-diabetes-drug-group-sglt2- inhibitors.
htmlDisclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.
This article is also not a treatment plan recommendation
.
For guidance on treatment options, please visit a regular hospital
.